Benzinga | May 19, 2021 09:16AM EDT

TELA Bio Launches Post Market Study Of OviTex In Hernia Surgery

* TELA Bio Inc (NASDAQ: TELA) has launched its second post-market study, BRAVO II, to evaluate the clinical performance of OviTex Reinforced Tissue Matrices in the robotic repair of ventral hernias.

* The study will enroll up to 100 subjects with patient follow-up at 90 days, 12 months, and 24 months.

* Study researchers will primarily monitor the incidence of early postoperative surgical site occurrences, wound-related events, and other complications within three months of surgery.

* Secondarily, researchers will monitor the incidence of true hernia recurrence, surgical site occurrences, and other complications occurring after three months post-surgery.

* Patient-reported outcomes will be evaluated and recorded using quality of life and pain assessments.

* Price Action: TELA shares closed at $13.43 on Tuesday.